In a nutshell This phase 3 trial will investigate the effectiveness of pembrolizumab (Keytruda) in non-small cell lung cancer (NSCLC). The main outcomes will be the rates of survival without any signs and symptoms of cancer and overall survival. The details NSCLC is usually treated with a combination of surgery to remove tumors and...
Read MoreIn a nutshell This trial aims to evaluate the safety and effectiveness of pembrolizumab (Keytruda) in stopping cancer coming back, compared to placebo in participants with surgically resected high-risk stage II melanoma. The main outcome that will be measured is how long patients go without cancer coming back (recurrence-free...
Read More
In a nutshell This multicenter phase 3 clinical trial will test the effectiveness of nivolumab (Opdivo) after surgery and chemotherapy in stage 1b to 3a non-small cell lung cancer (NSCLC). The primary outcome will be measured by the length of time the patient survives without signs of the cancer and the overall survival rate for up to 10...
Read More
In a nutshell This phase 1/2 trial aims to test the safety and effectiveness of a combined treatment with the new vaccine LPV7 and TLR agonists in advanced melanoma patients after surgery. The main outcome to be measured will be the treatment toxicity and response of the tumors to the treatment. This trial is recruiting in Houston, Texas and...
Read More
Hormonal therapy—also known as androgen deprivation therapy—has long been used to treat prostate cancer. But how does it work? And what are the potential side effects? Prostate cancer experts Drs. Jeri Kim and Sumit K. Subudhi, from MD Anderson Cancer Center, explore approved hormonal therapy...
Read More
Dr. Michael Wong from the University of Southern California, Norris Comprehensive Cancer Center considers the correlation between patients’ responses to treatment and the eventuality of stopping treatment. Dr. Wong argues disease and treatment differ from patient to patient. Tune in to learn more. Transcript Donna: I’m Donna...
Read More
One out of 10 people will be diagnosed with melanoma over their lifetime. While this used to be a death sentence of only months, research has made great strides over the last decade, extending life and hope by years. Dr. Sapna Patel, assistant professor in the Department of Melanoma Medical Oncology at the University of Texas MD Anderson...
Read More
In a nutshell The authors determined whether immune cell levels influenced overall survival (patients still alive following treatment) in prostate cancer patients following radiotherapy. Some background Radiotherapy is a common treatment for localized prostate cancer (cancer contained within the prostate gland). It involves...
Read More
In a nutshell The authors assessed the effectiveness of a specific radiation therapy called plaque brachytherapy in treating eye melanoma. Some background Uveal melanoma is cancer (melanoma) of the eye involving three parts of an eye (iris, ciliary body or choroid) – together known as the uvea. Chorodial melanoma is...
Read More
In a nutshell The authors aimed to determine whether hormone therapy alone or hormone therapy combined with radiation improved survival in prostate cancer patients. Some background Hormone therapy is a type of prostate cancer treatment that targets the male sex hormones active in prostate cancer, such as testosterone. Radiation therapy...
Read More
In a nutshell The objective of this paper was to determine how skin cancer patients with tumor thickness of > 4mm could benefit from a diagnostic procedure known as sentinel lymph node biopsy. Some background Melanoma is a type of cancer that starts in color-producing cells of the skin. It can grow deep into the inner layers of skin...
Read More
In a nutshell The authors evaluated the long-term results of escalating high dose radiotherapy for localized prostate cancer. Some background In the treatment of localized prostate cancer (cancer that has not spread beyond the prostate), improved radiotherapy techniques such as conformal radiotherapy allow high treatment doses to be...
Read More
